Origin Protocol Price Prediction 2025, 2026 – 2030: Is OGN A Good Investment?
Origin Protocol Price Prediction 2025, 2026 – 2030: Is OGN A Good Investment?
Organon to acquire Dermavant for $1.2 billion
OGN & OGV merger finalized, Enhancing blockchain unity
Significant Growth in Origin Protocol’s OGN Following Strategic Merge Announcement
Origin Protocol’s OGN and OGV Tokens Will Be Merged to Improve Ethereum Liquid Staking
OGN Failed to Hold Above Critical Resistance! What’s Next? Current OGN Coin Analysis!
2.51BUSD
See which Billionaires own this investment
Type
Common Stock
Exchange
NYSE
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US68622V1061
CUSIP
68622V106
Sector
Healthcare
Industry
Drug Manufacturers - General
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
3.28
PEG Ratio
-
Book Value
2.10
Dividend Share
1.12
Dividend Yield
0.83%
Earnings Share
2.88
Wall Street Target Price
14.00
EPS Estimate Current Year
3.86
EPS Estimate Next Year
4.08
EPS Estimate Current Quarter
0.8934
EPS Estimate Next Quarter
0.8965
Most Recent Quarter
-
Revenue TTM
6,294,000,128
Gross Profit TTM
3,599,000,064
EBITDA
1,695,000,064
Profit Margin
11.92%
Return On Assets TTM
6.98%
Return On Equity TTM
254.24%
Revenue Per Share TTM
24.434
Qtly Revenue Growth YOY
-6.70%
Diluted Eps TTM
2.88
Qtly Earnings Growth YOY
-57.70%
Trailing PE
3.28
Forward PE
5
Price Sales TTM
0.3907
Price Book MRQ
4.5372
Enterprise Value Revenue
1
Enterprise Value EBITDA
7
324.56
1.31%771.50
1.24%40.09
0.53%163.70
0.40%114.61
0.18%118.70
0.03%142.02
0.00%337.60
0.00%64.58
-1.31%189.35
-1.15%